ClinicalTrials.gg
RecruitingNCT07114367POTENTIAL-MUpdated Jan 30, 2026

NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma

A Phase 1 interventional study of NB02 (Poseltinib) in Non Hodgkin Lymphoma (NHL), sponsored by NOBO Medicine. Recruiting at 6 sites in South Korea. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by NOBO Medicine · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 105 studies in Lymphoma, Non-Hodgkin with a site in Korea, Republic of — 17 open to participants now, 38 under way, 13 of them phase 3. Lymphoma, Non-Hodgkin · Korea, Republic of.

Planned enrollment
99th of 101
9 · median 130
Started
2025
with 4 others
Phase 1
22 of 105
3 open now
Primary completion
2026-12
later than 6 of 37 live
Registered
102nd of 105
by date

Among the 105 studies in Lymphoma, Non-Hodgkin with a site in Korea, Republic of, this one is the 99th largest by planned enrollment of the 101 interventional ones that give a count, is one of 5 that started in 2025, is one of 22 in phase 1, reaches primary completion later than 6 of the 37 other live ones, and was the 102nd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

17 of the 105 studies in Lymphoma, Non-Hodgkin with a site in Korea, Republic of are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Lymphoma, Non-Hodgkin with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL

Read the detailed description

The study will conduct dose-finding. The dose-finding will be set as 3+3 design to seek candidates for optimal doses. Patients will receive study drugs to determine the MTD and/or OBD. In this study, OBD is defined as the most reasonable dose considering the benefit/risk ratio from available non-clinical and clinical data. The OBD will be determined based on available safety, PK/PD, and preliminary efficacy data, with a focus on identifying the dose that optimally balances clinical activity and tolerability.

03

Conditions studied

  • Non Hodgkin Lymphoma (NHL)

Keywords

  • Relapsed
  • Refractory
  • Lymphoma
  • NHL
  • FL
  • MCL
  • MZL
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 19 to 80 years.
  2. Patients must voluntarily agree to participate in the study and provide written prior to any study-related procedures.
  3. Patients with confirmed follicular lymphoma, mantle cell lymphoma or marginal zone lymphoma.
  4. Patients who have received more than two .
  5. based on Lugano classification.
  6. (ECOG) performance status of ≤ 2.
  7. Adequate organ function including:

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with NB02 (poseltinib).
  2. Patients who have experienced progression on BTKi mono or BTKi containing regimen (However, patients who discontinued treatment due to adverse-effect-related intolerance or for economic or social reasons remain eligible for enrollment).
  3. Unable to take oral medication.
  4. Inability to comply with study and follow-up procedures.
  5. Concurrent use of other drugs or enrollment in another clinical trial within 4 weeks prior to study drug administration.
  6. Patients who have previously been treated with NB02 (poseltinib) or any other BTK inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib).
  7. Known , and infection with active diseases
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    NB02 (Poseltinib)

    Dose Level 1 Dose Level 2 Dose Level 3

    Drug: NB02 (Poseltinib)

Interventions

06

What researchers measure

Primary outcomes

  1. MTD(maximum tolerated dose) or OBD(optimal biological dose)

    MTD(maximum tolerated dose) or OBD(optimal biological dose)

    Time frame: Approximately 48 Months

  2. AEs

    AEs

    Time frame: Approximately 48 Months

Secondary outcomes

  1. Pharmacokinetic (PK) Ctrough

    Pharmacokinetic (PK) parameters from plasma samples

    Time frame: Day 147

  2. Pharmacokinetic (PK) t1/2

    Pharmacokinetic (PK) parameters from plasma samples

    Time frame: Day 147

  3. Pharmacokinetic (PK) CL/F

    Pharmacokinetic (PK) parameters from plasma samples

    Time frame: Day 147

  4. Pharmacokinetic (PK) Vz/F

    Pharmacokinetic (PK) parameters from plasma samples

    Time frame: Day 147

  5. Pharmacokinetic (PK) Cmax

    Pharmacokinetic (PK) parameters from plasma samples

    Time frame: Day 147

  6. Pharmacokinetic (PK) AUCtau

    Pharmacokinetic (PK) parameters from plasma samples

    Time frame: Day 147

  7. Pharmacokinetic (PK) Tmax

    Pharmacokinetic (PK) parameters from plasma samples

    Time frame: Day 147

  8. Overall response rate (ORR)

    To evaluate preliminary anti-tumor activity

    Time frame: Approximately 48 Months

  9. Duration of response (DoR)

    To evaluate preliminary anti-tumor activity

    Time frame: Approximately 48 Months

  10. Time to response (TTR)

    To evaluate preliminary anti-tumor activity

    Time frame: Approximately 48 Months

  11. Progression-free survival (PFS)

    To evaluate preliminary anti-tumor activity

    Time frame: Approximately 48 Months

  12. Overall Survival (OS)

    To evaluate preliminary anti-tumor activity

    Time frame: Approximately 48 Months

07

Study locations

6 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 12 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Aug 11, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07114367
Lead sponsor
NOBO Medicine
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Dec 2, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poseltinib

Start the discussion